Diana Luftner

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. pmc Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
    Francisco J Esteva
    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 7:R436-43. 2005
  2. ncbi Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study
    D Luftner
    Medizin Klinik II, Charite, Humboldt Universitat Berlin, Germany
    Invest New Drugs 16:141-6. 1998
  3. ncbi Perspectives of immunotherapy in metastatic breast cancer
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsmedizin Berlin, Charite, Campus Mitte, Humboldt Universitat zu Berlin, 10117 Berlin, Germany
    Anticancer Res 25:4599-604. 2005
  4. ncbi Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany--final results of a survey among german breast cancer specialists
    Diana Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsmedizin Berlin, Charite, Humboldt Universitat zu Berlin, Germany
    Onkologie 28:639-44. 2005
  5. ncbi PINP as serum marker of metastatic spread to the bone in breast cancer patients
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsmedizin Berlin, Charite, Campus Mitte, Humboldt Universitat zu Berlin, Germany
    Anticancer Res 25:1491-9. 2005
  6. ncbi ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsmedizin Berlin, Humboldt Universitat zu Berlin, Berlin Germany
    Int J Biol Markers 19:175-82. 2004
  7. ncbi Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer
    Diana Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat zu Berlin, 10117 Berlin, Germany
    Anticancer Res 24:895-906. 2004
  8. ncbi Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Humboldt Universitat, Berlin, Germany
    Int J Biol Markers 19:1-13. 2004
  9. ncbi [Anemia and neutropenia in oncologic patients: modern growth factors simplify therapy]
    Diana Luftner
    Medizinische Klinik und Poliklinik II des Universitätsklinikums Charité, Humboldt Universitat zu Berlin
    Pflege Z 56:784-7. 2003
  10. ncbi Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat zu Berlin, Berlin, Germany
    Breast Cancer Res Treat 80:245-55. 2003

Detail Information

Publications30

  1. pmc Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
    Francisco J Esteva
    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 7:R436-43. 2005
    ..We also sought to determine whether early changes in serum HER2/neu concentrations could be a predictor of progression-free survival...
  2. ncbi Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study
    D Luftner
    Medizin Klinik II, Charite, Humboldt Universitat Berlin, Germany
    Invest New Drugs 16:141-6. 1998
    ..We conclude that the combination of gemcitabine and epirubicin is well tolerated and has promising activity. A phase II study is underway with gemcitabine 1000 mg/m2 and epirubicin 15 mg/m2 on days 1, 8 and 15 of a 28 day cycle...
  3. ncbi Perspectives of immunotherapy in metastatic breast cancer
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsmedizin Berlin, Charite, Campus Mitte, Humboldt Universitat zu Berlin, 10117 Berlin, Germany
    Anticancer Res 25:4599-604. 2005
    ..Last but not least, the most important prerequisite for the optimal efficacy of Herceptin-based therapy remains a very strict selection of those patients with tumours that have HER-2/neu over-expression...
  4. ncbi Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany--final results of a survey among german breast cancer specialists
    Diana Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsmedizin Berlin, Charite, Humboldt Universitat zu Berlin, Germany
    Onkologie 28:639-44. 2005
    ..We conducted a survey among breast specialists of the German Society of Senology...
  5. ncbi PINP as serum marker of metastatic spread to the bone in breast cancer patients
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsmedizin Berlin, Charite, Campus Mitte, Humboldt Universitat zu Berlin, Germany
    Anticancer Res 25:1491-9. 2005
    ..We investigated the utility of total PINP in breast cancer patients at different stages of the disease...
  6. ncbi ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsmedizin Berlin, Humboldt Universitat zu Berlin, Berlin Germany
    Int J Biol Markers 19:175-82. 2004
    ....
  7. ncbi Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer
    Diana Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat zu Berlin, 10117 Berlin, Germany
    Anticancer Res 24:895-906. 2004
    ..022). Considering the high impact of progression-free survival and duration of response as outcome parameters, the sHER-2/neu status is a predictive indicator for benefit from paclitaxel chemotherapy...
  8. ncbi Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Humboldt Universitat, Berlin, Germany
    Int J Biol Markers 19:1-13. 2004
    ..These HER-2/neu tissue results were correlated with the serum HER-2/neu (sHER-2/neu) levels at the time of metastatic spread...
  9. ncbi [Anemia and neutropenia in oncologic patients: modern growth factors simplify therapy]
    Diana Luftner
    Medizinische Klinik und Poliklinik II des Universitätsklinikums Charité, Humboldt Universitat zu Berlin
    Pflege Z 56:784-7. 2003
  10. ncbi Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat zu Berlin, Berlin, Germany
    Breast Cancer Res Treat 80:245-55. 2003
    ..Utilizing the circulating antigen of HER-2/neu in serum (sHER-2/neu) as a surrogate marker we investigated whether ovarian ablation by adjuvant therapy leads to an upregulation of HER-2/neu in breast cancer patients...
  11. ncbi Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer
    D Luftner
    Medizinische Klinik und Poliklinik II, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat zu Berlin, Schumannstr 20 21, 10117 Berlin, Germany
    Anticancer Res 23:1017-26. 2003
    ..29 as mass tumor marker in 73 breast cancer patients with bone metastases under specific antitumor therapy and supportive treatment with pamidronate...
  12. ncbi Serum HER-2/neu in the management of breast cancer patients
    Diana Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat zu Berlin, Schumannstr 20 21, 10117 Berlin, Germany
    Clin Biochem 36:233-40. 2003
    ..29 and CEA, which are not targeted by specific forms of systemic therapy...
  13. ncbi Gemcitabine for palliative treatment in metastatic breast cancer
    D Luftner
    Medizinische Klinik und Poliklinik II, Universitätsklinik Charité, Schwerpunkt Onkologie und Hamatologie, Humboldt Universitat Berlin, Germany
    J Cancer Res Clin Oncol 124:527-31. 1998
    ..Phase I experiences with long-time infusion schedules reveal good feasibility and high patient acceptance...
  14. ncbi c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy
    D Luftner
    Medizinische Klinik, Humboldt Universitat Berlin, Germany
    Int J Biol Markers 14:55-9. 1999
    ....
  15. ncbi The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment
    D Luftner
    Medizinische Klinik und Poliklinik II, Humboldt Universitat Berlin, Germany
    Anticancer Res 19:2537-44. 1999
    ..Urinary deoxypyridinoline (DPD)-crosslinks have been shown to be a highly specific parameter for type I collagen metabolism...
  16. ncbi Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer
    D Luftner
    Medizinische Klinik und Poliklinik II, Universitatsklinikum Charite, Humboldt Universitat Berlin, Germany
    Anticancer Res 19:3583-90. 1999
    ..Morbidity and mortality, disease-free- and overall survival were analysed in an adjuvant high-dose chemotherapy (HDCT) study with ifosfamide and epirubicin for high-risk (> or = 10 positive lymph nodes) breast cancer...
  17. ncbi Tumor type M2 pyruvate kinase expression in advanced breast cancer
    D Luftner
    Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat Berlin, Schumannstr 20 21, 10117 Berlin, Germany
    Anticancer Res 20:5077-82. 2000
    ..We investigated this marker in 67 patients with advanced breast cancer (ABC) in comparison to healthy controls...
  18. ncbi A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer
    D Lüfter
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Campus Mitte, Schumannstr 20 21, 10117 Berlin, Germany
    Anticancer Res 20:5099-105. 2000
    ..We compared a specific marker of bone resorption, urinary deoxypyridinoline (DPD)-crosslinks, with serum calcium (Ca), alkaline phosphatase (AP) and CA27.29, to evaluate the status of bone metastases in patients with breast cancer...
  19. ncbi Biomarkers and imaging in non-malignant and malignant osteomalacia
    D Luftner
    Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hamatologie, Universitatsklinikum Charite, Humboldt Universitat, Berlin, Germany
    Int J Biol Markers 16:136-41. 2001
    ..This example underlines the validity of DPD and bone-AP as indicators of increased bone metabolism: not only were they the parameters with the highest baseline deviation, but they were also the last to normalize...
  20. ncbi Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer
    D Luftner
    Medizinische Klinik und Poliklinik II, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat zu Berlin, Schumannstr 20 21, 10117 Berlin, Germany
    Anticancer Res 23:991-7. 2003
    ..One target of phosphorylation processes is assumed to be the tumor type M2 isoenzyme of pyruvate kinase (TuM2-PK) which has been shown to be elevated in metastatic breast cancer...
  21. ncbi Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer stu
    Peter Schmid
    Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Humboldt Universitat zu Berlin, Germany
    Anticancer Res 22:2325-32. 2002
    ....
  22. doi Prescription pattern of aromatase inhibitors for the adjuvant therapy of breast cancer in Germany - results of the second survey among gynaecologists and medical oncologists
    Diana Luftner
    Medizinische Klinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie, Charite, Campus Mitte, Universitatsmedizin Berlin, Germany
    Onkologie 31:19-25. 2008
    ..In sequence to our first survey in 2004 on antihormonal therapy with aromatase inhibitors (AIs), we conducted a second survey on the prescription practice in 2005...
  23. ncbi Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes
    Sherko Kummel
    Department of Senology, University Medicine Berlin, Campus Charite Mitte, Berlin, Germany
    Anticancer Res 26:1719-26. 2006
    ..The goal of the present study was to investigate the changes in concentration of the important lymph-angiogenesis factors vascular endothelium-derived growth factor (VEGF) and VEGF-D under adjuvant chemotherapy...
  24. ncbi Management of Metastatic Bone Disease Algorithms for Diagnostics and Treatment
    Christian F Jehn
    Department of Hematology, Oncology and Tumor Immunology, University Hospital Charite, Berlin, Germany
    Anticancer Res 36:2631-7. 2016
    ..Bone is a frequent site of metastases in advanced cancer and is associated with significant skeletal morbidity. Current treatment options are aimed at preserving and improving functional independence and quality of life...
  25. ncbi Lack of HER-2/neu overexpression in non-Hodgkin's lymphoma
    Diana Luftner
    Medizinische Klinik und Poliklinik II Schwerpunkt Onkologie und Hämatologie Universitätsmedizin Berlin, Charite, Campus Mitte, Humboldt Universitat zu Berlin, Schumannstr 20 21, 10117 Berlin, Germany
    Anticancer Res 24:3233-7. 2004
    ..Single reports mention HER-2/neu positivity in hematological malignancies like Hodgkins's disease and even diffuse large-cell lymphoma...
  26. ncbi Nuclear matrix proteins as biomarkers for breast cancer
    Diana Luftner
    Medizinische Klinik and Poliklinik II, Charite, Campus Mitte, Schumannster 20 21, 10117 Berlin, Germany
    Expert Rev Mol Diagn 2:23-31. 2002
    ..3 kD serum protein, designated NMP66, can distinguish malignant disease from benign conditions and normal controls. NMP66 is now being evaluated as a potential biomarker for early breast cancer detection in large-scale clinical trials...
  27. ncbi Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia
    Diana Luftner
    Medizinische Klinik und Poliklinik II mit Schwerpunkt Onkologie und Hämatologie, Charite Campus Mitte, Berlin, Germany
    Onkologie 28:595-602. 2005
    ....
  28. ncbi Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer
    Kristoph Jahnke
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Anticancer Res 31:317-23. 2011
    ..A randomized phase II trial was conducted to determine if two non-platinum protocols are able to yield a similar efficacy and toxicity profile as compared to two platinum-based doublets in advanced non-small cell lung cancer (NSCLC)...
  29. doi Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration
    Jeanette Seidel
    Charite Campus Mitte, Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Humboldt Universitat zu Berlin, Germany
    Biochem Biophys Res Commun 414:226-32. 2011
    ..Nonetheless, other TKIs might offer therapeutic approaches for CDCP1-targeted breast cancer therapy and should be studied considering this aspect...
  30. doi Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer
    Christian Friedrich Jehn
    Department of Oncology and Hematology, University Hospital Charite, Berlin, Germany
    Integr Cancer Ther 9:270-5. 2010
    ..Patients with cancer show elevated prevalence rates for depression. The objective of this cross-sectional study was to investigate the associations between these abnormalities and depression...